Use of moclobemide in children with attention deficit hyperactivity disorder

Trott, Götz‐Erik; Friese, H.-J.; Menzel, M.; Nissen, Gerhardt

doi:10.1007/bf02246258

Cited by 54 publications

(13 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Other potential therapeutic uses and indications can be smoking cessation, attention deficit, hyperactivity disorder and cognitive deficits in dementia for moclobemide [2][3][4].…”

Section: Therapeutic Use: Indications and Clinical Efficacymentioning

confidence: 99%

Clinical Applications of MAO-Inhibitors

Riederer

Lachenmayer²,

Laux³

2004

Current Medicinal Chemistry

207

115

View full text Add to dashboard Cite

Monoamine oxidase inhibitors (MAO-I) have been useful in the treatment of both psychiatric and neurological disorders over centuries. Here we focus on the development of this drug treatment. Focus is given on the use of irreversible MAO-I's as well as on reversible ones. Benefit and side effects are reported for Parkinson's disease, Alzheimer's dementia, depression syndrome and panic disorders. The preclinical and clinical effects of selegiline with regard to neuroprotection are highlightened and the conclusion is drawn that there is good evidence for a clinical neuroprotective capacity based on the assumption that the 50 percent recovery of MAO-B is obtained already after a 10 days withdrawal of selegiline. There is also a focus on selegilines metabolism to amphetamine and metamphetamine. In order to avoid any such effects of metabolic compounds on the cardiovascular system Zydis Selegiline, a melt-tablet avoid of major metabolism to amphetamine and metamphetamine is described in detail. Developments in MAO-I research are discussed in detail as there are moclobemide, lacabemide, rasagiline. Interactions of MAO-I' with tricyclics and serotonin selective reuptake inhibitors (SSRI's) are described as there is mentioning of interactions of MAO-I's with other compounds in general. Tables and figures report on clinical studies and on pharmacological properties of MAO-I's.

show abstract

“…Other potential therapeutic uses and indications can be smoking cessation, attention deficit, hyperactivity disorder and cognitive deficits in dementia for moclobemide [2][3][4].…”

Section: Therapeutic Use: Indications and Clinical Efficacymentioning

confidence: 99%

Clinical Applications of MAO-Inhibitors

Riederer

Lachenmayer²,

Laux³

2004

Current Medicinal Chemistry

207

115

View full text Add to dashboard Cite

show abstract

“…Rommelse et al 2008) found a significant association of a more active MAOA allele with ADHD; this would depress vesicular stores and exocytotic release of dopamine and serotonin, but the concentration of synaptic transmitter would be restored by reuptake inhibitors such as MPH (Guimarães et al 2009). In several small studies, MAO inhibitors were shown to be as effective as amphetamine in reducing ADHD symptoms with comparable or fewer side effects (Mohammadi et al 2004;Rubinstein et al 2006;Trott et al 1992;Zametkin et al 1985). However, most of these studies used orally administered l-deprenyl (selegiline), which is an irreversible inhibitor of the type B form of MAO.…”

Section: Sex Cigarettes and Maomentioning

confidence: 99%

“…If overactive MAO plays a role in ADHD, inhibitors of MAO should ameliorate its symptoms, as they will slow the deamination of MAO (Bortolato et al 2008). Indeed, selegiline is just as effective as methylphenidate in treating the symptoms of ADHD (Akhondzadeh et al 2003;Mohammadi et al 2004), as is another MAO inhibitor, moclobemide (Trott et al 1992). Whereas the advantage of these drugs over more traditional pharmacotherapies is not established, new MAOIs (Youdim and Weinstock 2004) and routes of administration (Azzaro et al 2007) may lead to more effective pharmacotherapies.…”

Section: Materials Causes: Brain Modificationmentioning

confidence: 99%

The Four Causes of ADHD: A Framework

Killeen

Tannock

Sagvolden

2011

Behavioral Neuroscience of Attention Deficit Hyperactivity Disorder and Its Treatment

View full text Add to dashboard Cite

In addition to the symptoms singled out by the diagnostic criteria for Attention-Deficit Hyperactivity Disorder (ADHD), a comprehensive definition should inform us of the events that trigger ADHD in both its acute and chronic manifestations; the neurobiology that underlies it; and the evolutionary forces that have kept it in the germ line of our species. These factors are organized in terms of Aristotle's four kinds of "causes," or explanations: formal, efficient, material, and final. This framework systematizes the nosology, biology, psychology, and evolutionary pressures that cause ADHD.

show abstract

“…Outside the psychostimulants, noradrenergic and dopaminergic active compounds including monoamine oxidase inhibitors [32,33], secondary amine tricyclic antidepressants [34] and bupropion [35] have been found superior to placebo in controlled clinical studies. Possible advantages of these compounds over stimulants include a longer duration of action without symptom rebound, minimal risk of abuse and as the potential treatment of comorbid internalizing symptoms.…”

Section: Second-line Agentsmentioning

confidence: 99%

Psychopharmacological Treatment of Attention-Deficit Hyperactivity Disorder in Adults

Trott¹

2009

Attention-Deficit Hyperactivity Disorder (ADHD) in Adults

View full text Add to dashboard Cite

Attention-deficit hyperactivity disorder (ADHD) in adults is a common disorder which results in a lot of secondary problems. Pharmacological treatment is essential in the management of ADHD. Stimulant treatment has for decades been proven to be effective and safe. Amphetamine was the first drug for this indication; most studies have been carried out with methylphenidate, which has been shown to be very effective and well tolerated. Newer extended-release methylphenidate preparations have considerable advantages. Because of hepatic side effects, pemoline no longer plays a role. Modafinil seems to have comparable effects like amphetamine. Atomoxetine is a potent norepinephrine-specific reuptake inhibitor which is approved for the treatment of ADHD in children, adolescents and adults. Tricyclic antidepressants may be third-line agents. Bupropion targets both ADHD and depressive symptoms which are frequent comorbid conditions. Clonidine and guanfacine have positive effects in patients with ADHD and comorbid tics. Several other compounds may be beneficial in ADHD treatment.Attention-deficit hyperactivity disorder (ADHD) has been increasingly recognized as a chronic condition [1]. Already in the 1980s, Paul Wender [2] realized that ADHD patients remain in treatment also in early adulthood. Approximately one-to twothirds of children with ADHD continue to manifest at least some clinically significant symptoms of the disorder into adulthood [3]. The symptom of hyperactivity shows best remission in adolescence, whereas impulsivity and inattention decline only slightly [4]. The prevalence of adult ADHD has been estimated in a recent study to be 4.4% [5].There is common consent that untreated ADHD has a high risk of secondary problems in later life [6]. Studies in adults who have been diagnosed in childhood showed significantly higher rates of lower academic degrees, substance abuse and delinquency, impaired problems in occupational integration, more unwanted pregnancies, more children, more divorces and more contacts to medical services [7].

show abstract

Use of moclobemide in children with attention deficit hyperactivity disorder

Cited by 54 publications

References 9 publications

Clinical Applications of MAO-Inhibitors

Clinical Applications of MAO-Inhibitors

The Four Causes of ADHD: A Framework

Psychopharmacological Treatment of Attention-Deficit Hyperactivity Disorder in Adults

Contact Info

Product

Resources

About